On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia
Abstract
:1. Introduction
2. Methods
Measles Immunity Profile
3. Results
3.1. Measles and Rubella Case-Based Surveillance Performance
3.2. Measles Immunity Profile
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Vynnycky, E.; Adams, E.; Cutts, F.; Reef, S.; Navar, A.; Simons, E.; Yoshida, L.-M.; Brown, D.W.J.; Jackson, C.; Strebel, P.; et al. Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996–2010: A Systematic Review. PLoS ONE 2016, 11, e0149160. [Google Scholar] [CrossRef]
- Patel, M.; Gacic Dobo, M.; Strebel, P.; Dabbagh, A.; Mulders, M.; Okwo Bele, J.-M.; Dumolard, L.; Rota, P.; Kretsinger, K.; Goodson, J. Progress Toward Regional Measles Elimination—Worldwide, 2000–2015. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
- United Nations General Assembly. United Nations Millennium Declaration; United Nations General Assembly: New York, NY, USA, 2000; Available online: http://www.un.org/millenniumgoals/ (accessed on 10 May 2017).
- World Health Organization. Global Vaccine Action Plan 2011–2020; World Health Organization: Geneva, Switzerland, 2012. Available online: http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/index.html (accessed on 15 January 2020).
- Strebel, P.M.; Cochi, S.L.; Hoekstra, E.; Rota, P.A.; Featherstone, D.; Bellini, W.J.; Katz, S.L. A World without Measles. J. Infect. Dis. 2011, 204 (Suppl. 1), S1–S3. [Google Scholar] [CrossRef] [PubMed]
- Durrheim, D.N.; Crowcroft, N.S. The price of delaying measles eradication. Lancet Public Health 2017, 2, e130–e131. [Google Scholar] [CrossRef]
- Robbins, F.C. Prospects for Worldwide Control of Measles: Discussion I. Rev. Infect. Dis. 1983, 5, 619–620. [Google Scholar] [CrossRef]
- Dowdle, W.; Cochi, S. The principles and feasibility of disease eradication. Vaccine 2011, 29 (Suppl. 4), D70–D73. [Google Scholar] [CrossRef]
- Thompson, K.M.; Badizadegan, N. Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases. Risk Anal. 2017, in press. [Google Scholar] [CrossRef]
- International Task Force for Disease Eradication. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. 1993, 42, 1–38. [Google Scholar]
- Strebel, P.M.; Papania, M.J.; Gastañaduy, P.A.; Goodson, J.L. Measles Vaccines. In Vaccines, 7th ed.; Plotkin, S., Orenstein, W., Offit, P., Edwards, K.M., Eds.; Elisevier: Philadelphia, PA, USA, 2018; pp. 579–618. [Google Scholar]
- Shattock, A.J.; Johnson, H.C.; Sim, S.Y.; Carter, A.; Lambach, P.; Hutubessy, R.C.W.; Thompson, K.M.; Badizadegan, K.; Lambert, B.; Ferrari, M.J.; et al. Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization. Lancet 2024, 403, 2307–2316. [Google Scholar] [CrossRef]
- WHO. Measles and Rubella Strategic Framework: 2021–2030. Available online: https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030 (accessed on 5 October 2021).
- Goodson, J.L.; Alexander, J.P.; Linkins, R.W.; Orenstein, W.A. Measles and rubella elimination: Learning from polio eradication and moving forward with a diagonal approach. Expert Rev. Vaccines 2017, 16, 1203–1216. [Google Scholar] [CrossRef]
- World Health Organization. Immunization Agenda 2030 (IA2030); World Health Organization: Geneva, Switzerland, 2020. Available online: http://www.immunizationagenda2030.org/ (accessed on 1 June 2024).
- World Health Organization. Measles Outbreak Guide; World Health Organization: Geneva, Switzerland, 2022.
- Guerra, F.M.; Bolotin, S.; Lim, G.; Heffernan, J.; Deeks, S.L.; Li, Y.; Crowcroft, N.S. The basic reproduction number (R0) of measles: A systematic review. Lancet Infect. Dis. 2017, 17, e420–e428. [Google Scholar] [CrossRef] [PubMed]
- Rota, P.; Moss, W.; Takeda, M.; de Swart, R.; Thompson, K.; Goodson, J. Measles. Nat. Rev. Dis. Primers 2016, 2, 16049. [Google Scholar] [CrossRef] [PubMed]
- Nakase, T.; Brownwright, T.; Okunromade, O.; Egwuenu, A.; Ogunbode, O.; Lawal, B.; Akanbi, K.; Grant, G.; Bassey, O.O.; Coughlin, M.M.; et al. The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria. Vaccine 2024, 42, 125982. [Google Scholar] [CrossRef]
- World Health Organization. Meeting of the International Task Force for Disease Eradication, November 2015. Wkly. Epidemiol. Rec. 2016, 91, 61–71. [Google Scholar]
- Nguku, P.M.; Sharif, S.K.; Mutonga, D.; Amwayi, S.; Omolo, J.; Mohammed, O.; Farnon, E.C.; Gould, L.H.; Lederman, E.; Rao, C.; et al. An investigation of a major outbreak of Rift Valley fever in Kenya: 2006–2007. Am. J. Trop. Med. Hyg. 2010, 83, 5–13. [Google Scholar] [CrossRef]
- Strebel, P.; Grabowsky, M.; Hoekstra, E.; Gay, A.; Cochi, S. Evolution and Contribution of a Global Partnership against Measles and Rubella, 2001–2023. Vaccines 2024, 12, 693. [Google Scholar] [CrossRef]
- Perry, R.; Gacic Dobo, M.; Dabbagh, A.; Mulders, M.; Strebel, P.; Okwo Bele, J.-M.; Rota, P.; Goodson, J. Progress toward regional measles elimination-worldwide, 2000–2013. MMWR Morb. Mortal. Wkly. Rep. 2014, 63, 1034–1038. [Google Scholar]
- World Health Organization. Global Measles and Rubella Strategic Plan 2012–2020. Available online: http://www.who.int/immunization/newsroom/Measles_Rubella_StrategicPlan_2012_2020.pdf (accessed on 15 January 2020).
- Regional Committee for Africa. Measles Elimination by 2020: A Strategy for the African Region; World Health Organization, Regional Office for Africa: Brazzaville, Congo, 2011. [Google Scholar]
- Regional Committee for Africa. Framework for the Implementation of the Immunization Agenda 2030 in the WHO African Region: Report of the Secretariat; World Health Organization, Regional Office for Africa: Brazzaville, Congo, 2021. [Google Scholar]
- Masresha, B.G.; Hatcher, C.; Lebo, E.; Tanifum, P.; Bwaka, A.M.; Minta, A.A.; Antoni, S.; Grant, G.B.; Perry, R.T.; O’Connor, P. Progress Toward Measles Elimination—African Region, 2017–2021. MMWR Morb. Mortal. Wkly. Rep. 2023, 72, 985–991. [Google Scholar] [CrossRef]
- Ou, A.C.; Zimmerman, L.A.; Alexander, J.P., Jr.; Crowcroft, N.S.; O’Connor, P.M.; Knapp, J.K. Progress Toward Rubella and Congenital Rubella Syndrome Elimination—Worldwide, 2012–2022. MMWR Morb. Mortal. Wkly. Rep. 2024, 73, 162–167. [Google Scholar] [CrossRef]
- World Bank. World Bank Country Economy Classification by Income. 2023. Available online: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed on 18 February 2024).
- United Nations Population Division. World Population Prospects. 2022. Available online: https://population.un.org/wpp/Download/Standard/Population/ (accessed on 28 April 2024).
- World Health Organization Organisation Mondiale de la Santé. Rubella vaccines: WHO position paper—July 2020—Note de synthèse: Position de l’OMS concernant les vaccins antirubéoleux. Wkly. Epidemiol. Rec. Relev. Épidémiol. Hebd. 2020, 95, 306–324. [Google Scholar]
- Namibia Ministry of Health and Social Services; Expanded Programme on Immunization. Namibia Strategic Plan for Expanded Programme on Immunization 2018–2022; WHO Namibia Country Office: Windhoek, Namibia, 2017. [Google Scholar]
- World Health Organization. Namibia: WHO and UNICEF Estimates of Immunization Coverage: 2022 Revision. 2023. Available online: https://cdn.who.int/media/docs/default-source/country-profiles/immunization/2023-country-profiles/immunization_nam_2023.pdf?sfvrsn=c1e915f0_3&download=true (accessed on 28 April 2024).
- Biellik, R.; Madema, S.; Taole, A.; Kutsulukuta, A.; Allies, E.; Eggers, R.; Ngcobo, N.; Nxumalo, M.; Shearley, A.; Mabuzane, E.; et al. First 5 years of measles elimination in southern Africa: 1996–2000. Lancet 2002, 359, 1564–1568. [Google Scholar] [CrossRef] [PubMed]
- McLean, A. After the honeymoon in measles control. Lancet 1995, 345, 272. [Google Scholar] [CrossRef]
- Shibeshi, M.E.; Masresha, B.G.; Smit, S.B.; Biellik, R.J.; Nicholson, J.L.; Muitherero, C.; Shivute, N.; Walker, O.; Reggis, K.; Goodson, J.L. Measles resurgence in southern Africa: Challenges to measles elimination. Vaccine 2014, 32, 1798–1807. [Google Scholar] [CrossRef]
- Ogbuanu, I.U.; Zeko, S.; Chu, S.Y.; Muroua, C.; Gerber, S.; De Wee, R.; Kretsinger, K.; Wannemuehler, K.; Gerndt, K.; Allies, M.; et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009–2010. Clin. Infect. Dis. 2014, 58, 1086–1092. [Google Scholar] [CrossRef] [PubMed]
- Ogbuanu, I.U.; Muroua, C.; Allies, M.; Chitala, K.; Gerber, S.; Shilunga, P.; Mhata, P.; Kriss, J.L.; Caparos, L.; Smit, S.B.; et al. Measles outbreak reveals measles susceptibility among adults in Namibia, 2009–2011. S. Afr. Med. J. 2016, 106, 715–720. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation African Regional Office. Measles and Rubella Case-Based Surveillance Data Analysis; Presented at measles technical meeting; WHO African Regional Office: Brazzaville, Congo, 2014. [Google Scholar]
- Jonas, A.; Cardemil, C.V.; Beukes, A.; Anderson, R.; Rota, P.A.; Bankamp, B.; Gary, H.E., Jr.; Sawadogo, S.; Patel, S.V.; Zeko, S.; et al. Rubella immunity among pregnant women aged 15–44 years, Namibia, 2010. Int. J. Infect. Dis. 2016, 49, 196–201. [Google Scholar] [CrossRef]
- Cardemil, C.V.; Jonas, A.; Beukes, A.; Anderson, R.; Rota, P.A.; Bankamp, B.; Gary, H.E., Jr.; Sawadogo, S.; Patel, S.V.; Zeko, S.; et al. Measles immunity among pregnant women aged 15–44 years in Namibia, 2008 and 2010. Int. J. Infect. Dis. 2016, 49, 189–195. [Google Scholar] [CrossRef]
- Cardemil, C.V.; Jonas, A.; Gerber, S.; Weldon, W.C., 3rd; Oberste, M.S.; Beukes, A.; Sawadogo, S.; Patel, S.V.; Zeko, S.; Muroua, C.; et al. Poliovirus immunity among pregnant females aged 15–44 years, Namibia, 2010. J. Infect. Dis. 2014, 210 (Suppl. 1), S136–S142. [Google Scholar] [CrossRef]
- Goodson, J.L.; Masresha, B.G.; Wannemuehler, K.; Uzicanin, A.; Cochi, S. Changing Epidemiology of Measles in Africa. J. Infect. Dis. 2011, 204, S205–S214. [Google Scholar] [CrossRef]
- Burton, A.; Monasch, R.; Lautenbach, B.; Gacic-Dobo, M.; Neill, M.; Karimov, R.; Wolfson, L.; Jones, G.; Birmingham, M. WHO and UNICEF estimates of national infant immunization coverage: Methods and processes. World Health Organ. Bull. World Health Organ. 2009, 87, 535–541. [Google Scholar] [CrossRef]
- Simons, E.; Mort, M.; Dabbagh, A.; Strebel, P.; Wolfson, L. Strategic planning for measles control: Using data to inform op-timal vaccination strategies. J. Infect. Dis. 2011, 204 (Suppl. S1), S28–S34. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization Organisation Mondiale de la Santé. Measles vaccines: WHO position paper—April 2017—Note de synthèse de l’OMS sur les vaccins contre la rougeole—Avril 2017. Wkly. Epidemiol. Rec. Relev. Épidémiol. Hebd. 2017, 92, 205–227. [Google Scholar]
- World Health Organization. Planning and Implementing High-Quality Supplementary Immunization Activities for Injectable Vaccines Using an Example of Measles and Rubella Vaccines: Field Guide; World Health Organization: Geneva, Switzerland, 2016.
- Namibia Ministry of Health and Social Services; Expanded Programme on Immunization. Namibia Measles and Measles-Rubella Campaign Technical Reports Reported to the World Health Organization (WHO). Presented at technical meeting; WHO African Regional Office: Congo, Brazzaville, 2012–2021.
- WHO Regional Office for Africa Office. African Regional Guidelines for Measles and rubella Surveillance. 2015. Available online: https://www.afro.who.int/sites/default/files/2017-06/who-african-regional-measles-and-rubella-surveillance-guidelines_updated-draft-version-april-2015_1.pdf (accessed on 28 April 2024).
- Luce, R.; Masresha, B.G.; Katsande, R.; Fall, A.; Shibeshi, M.E. The Impact of Recent Rubella Vaccine Introduction in 5 Countries in The African Region. J. Immunol. Sci. 2018, 16, 108–112. [Google Scholar] [CrossRef]
- Su, Q.; Ma, C.; Wen, N.; Fan, C.; Yang, H.; Wang, H.; Yin, Z.; Feng, Z.; Hao, L.; Yang, W. Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine. Vaccine 2018, 36, 2079–2085. [Google Scholar] [CrossRef]
- Castillo-Solorzano, C.; Marsigli, C.; Bravo-Alcantara, P.; Flannery, B.; Ruiz Matus, C.; Tambini, G.; Gross-Galiano, S.; Andrus, J.K. Elimination of rubella and congenital rubella syndrome in the Americas. J. Infect. Dis. 2011, 204 (Suppl 2), S571–S578. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Progress toward control of rubella and prevention of congenital rubella syndrome—Worldwide, 2009. MMWR Morb. Mortal. Wkly. Rep. 2010, 59, 1307–1310. [Google Scholar]
- Goodson, J.L.; Masresha, B.; Dosseh, A.; Byabamazima, C.; Nshimirimana, D.; Cochi, S.; Reef, S. Rubella Epidemiology in Africa in the Prevaccine Era, 2002–2009. J. Infect. Dis. 2011, 204, S215–S225. [Google Scholar] [CrossRef]
- Kidd, S.; Goodson, J.; Aramburu, J.; Morais, A.; Gaye, A.; Wannemuehler, K.; Buffington, J.; Gerber, S.; Wassilak, S.; Uzicanin, A. Poliomyelitis outbreaks in Angola genetically linked to India: Risk factors and implications for prevention of outbreaks due to wild poliovirus importations. Vaccine 2011, 29, 3760–3766. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Outbreak of polio in adults—Namibia, 2006. MMWR Morb. Mortal. Wkly. Rep. 2006, 55, 1198–1201. [Google Scholar]
- Kriss, J.; De Wee, R.; Lam, E.; Kaiser, R.; Shibeshi, M.; Ndevaetela, E.-E.; Muroua, C.; Shapumba, N.; Masresha, B.; Goodson, J. Development of the World Health Organization Measles Programmatic Risk Assessment Tool Using Experience from the 2009 Measles Outbreak in Namibia. Risk Anal. 2017, 37, 1072–1081. [Google Scholar] [CrossRef]
- The Nambia Ministry of Health and Social Services (MoHSS); ICF International. Namibia Demographic and Health Survey 2013; MoHSS/Namibia and ICF International: Windhoek, Namibia, 2014. [Google Scholar]
- Goodson, J.L.; Perry, R.T.; Mach, O.; Manyanga, D.; Luman, E.T.; Kitambi, M.; Kibona, M.; Wiesen, E.; Cairns, K.L. Measles outbreak in Tanzania, 2006–2007. Vaccine 2010, 28, 5979–5985. [Google Scholar] [CrossRef] [PubMed]
- Goodson, J.; Wiesen, E.; Perry, R.; Mach, O.; Kitambi, M.; Kibona, M.; Luman, E.; Cairns, K.L. Impact of measles outbreak response vaccination campaign in Dar es Salaam, Tanzania. Vaccine 2009, 27, 5870–5874. [Google Scholar] [CrossRef]
- Harris, R.C.; Chen, Y.; Côte, P.; Ardillon, A.; Nievera, M.C.; Ong-Lim, A.; Aiyamperumal, S.; Chong, C.P.; Kandasamy, K.V.; Mahenthiran, K.; et al. Impact of COVID-19 on routine immunisation in South-East Asia and Western Pacific: Disruptions and solutions. Lancet Reg. Health West Pac. 2021, 10, 100140. [Google Scholar] [CrossRef]
- Gaythorpe, K.A.; Abbas, K.; Huber, J.; Karachaliou, A.; Thakkar, N.; Woodruff, K.; Li, X.; Echeverria-Londono, S.; Ferrari, M.; Jackson, M.L.; et al. Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. Elife 2021, 10, 67023. [Google Scholar] [CrossRef] [PubMed]
- Hong, H.; Malfeld, S.; Smit, S.; Makhathini, L.; Fortuin, M.; Motsamai, T.; Tselana, D.; Manamela, M.J.; Motaze, N.V.; Ntshoe, G.; et al. A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine. PLoS ONE 2022, 17, e0265870. [Google Scholar] [CrossRef]
- Masresha, B.; Luce, R., Jr.; Tanifum, P.; Lebo, E.; Dosseh, A.; Mihigo, R. The African Region early experience with structures for the verification of measles elimination—A review. Pan Afr. Med. J. 2020, 35, 2. [Google Scholar] [CrossRef] [PubMed]
- WHO. Guidance for evaluating progress towards elimination of measles and rubella. Wkly. Epidemiol. Rec. 2018, 93, 544–552. [Google Scholar]
- Minta, A.A.; Ferrari, M.; Antoni, S.; Portnoy, A.; Sbarra, A.; Lambert, B.; Hatcher, C.; Hsu, C.H.; Ho, L.L.; Steulet, C.; et al. Progress Toward Measles Elimination—Worldwide, 2000–2022. MMWR Morb. Mortal. Wkly. Rep. 2023, 72, 1262–1268. [Google Scholar] [CrossRef]
- Andrus, J.K.; de Quadros, C.A.; Solórzano, C.C.; Periago, M.R.; Henderson, D.A. Measles and rubella eradication in the Americas. Vaccine 2011, 29 (Suppl. 4), D91–D96. [Google Scholar] [CrossRef]
Year | Type of SIAs | Target Age Group | Number of Persons Targeted | Number of Persons Vaccinated | Administrative Coverage | Proportion of Districts with ≥95% Coverage | SIA Coverage by Survey |
---|---|---|---|---|---|---|---|
2000 | M Follow-up | 9–59 months | 285,504 | 257,590 | 80% | N/A | N/A |
2003 | M Follow-up | 9–59 months | 340,000 | 318,240 | 94% | N/A | N/A |
2006 | M Follow-up | 9–59 months | 353,270 | 318,905 | 97% | N/A | N/A |
2009 | M Follow-up | 9–59 months | 246,501 | 256,006 | 104% | N/A | N/A |
2012 | M Follow-up | 9 months–15 years | 972,163 | 885,259 | 91% | 100% | 97% |
2016 | MR Catch-up | 9 months–39 years | 1,859,857 | 1,908,193 | 103% | 77% | N/A |
2022 | MR Follow-up | 9–59 months | 309,916 | 293,705 | 95% | 53% | N/A |
Setting * | Age Group | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time Period | Cases † | Female | Rural | Urban | <1 y | 1–4 y | 5–9 y | 10–14 y | ≥15 y | Women of Reproductive Age (15–49 y) | ||||||||||
Years | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Measles | 2010–2016 | 2698 | 1328 | 49 | 1124 | 65 | 602 | 35 | 74 | 3 | 708 | 26 | 568 | 21 | 342 | 13 | 707 | 26 | 702 | 29 |
2017–2023 | 113 | 49 | 43 | 31 | 27 | 82 | 73 | 0 | 0 | 44 | 39 | 47 | 42 | 8 | 7 | 3 | 3 | 3 | 3 | |
Rubella | 2010–2016 | 885 | 465 | 53 | 314 | 39 | 482 | 61 | 2 | 2 | 171 | 21 | 343 | 42 | 197 | 24 | 111 | 13 | 110 | 13 |
2017–2023 | 52 | 27 | 52 | 15 | 29 | 37 | 71 | 0 | 0 | 13 | 30 | 18 | 41 | 8 | 18 | 5 | 11 | 4 | 9 |
Year | % Districts that Investigated at Least One Measles-Suspected Case with a Blood Specimen per Year (Target: ≥ 80%) | Non-Measles Febrile Rash Illness Rate per 100,000 Population (Target: ≥ 2 per Million Population) |
---|---|---|
2010 | 82% | 22.6 |
2011 | 82% | 18.9 |
2012 | 73% | 16.0 |
2013 | 59% | 6.8 |
2014 | 73% | 16.5 |
2015 | 75% | 45.6 |
2016 | 85% | 10.9 |
2017 | 100% | 16.9 |
2018 | 91% | 11.3 |
2019 | 76% | 7.3 |
2020 | 76% | 7.8 |
2021 | 18% | 3.7 |
2022 | 68% | 5.5 |
2023 | 74% | 12.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Masresha, B.G.; Shibeshi, M.E.; de Wee, R.; Shapumba, N.; Sayi, T.; Reef, S.E.; Goodson, J.L. On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia. Vaccines 2024, 12, 957. https://doi.org/10.3390/vaccines12090957
Masresha BG, Shibeshi ME, de Wee R, Shapumba N, Sayi T, Reef SE, Goodson JL. On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia. Vaccines. 2024; 12(9):957. https://doi.org/10.3390/vaccines12090957
Chicago/Turabian StyleMasresha, Balcha G., Messeret E. Shibeshi, Roselina de Wee, Nicholas Shapumba, Takudzwa Sayi, Susan E. Reef, and James L. Goodson. 2024. "On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia" Vaccines 12, no. 9: 957. https://doi.org/10.3390/vaccines12090957